Orgasmic Disorder
2
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
GSKWellbutrin XL
S1 BiopharmaS1B-408
Clinical Trials (2)
Total enrollment: 78 patients across 2 trials
Female Orgasmic Disorder (FOD) and Wellbutrin XL
Start: May 2004Est. completion: Apr 200748 patients
Phase 2/3Completed
Study of S1B-408 in Women With Orgasmic Dysfunction
Start: Jul 2025Est. completion: Mar 202730 patients
Phase 2Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.